Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab and Tuvoraleimab + Bevacizumab + Chemotherapy in First-Line Advanced Mesothelioma
NCT07514793Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Apr 2026
- Primary completion
- Apr 2029
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab and pimivalimab in mesothelioma, sponsored by Fudan University. Primary endpoint: Objective Response Rate up to 2 years. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
iparomlimabpimivalimab
03
Conditions
mesothelioma
Beyond the preview
Go deeper on NCT07514793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07514793.